The Unmet Need Driving New Mechanisms in B-Cell Malignancies

Dr Shadman frames the clinical need for treatment mechanisms beyond conventional BTK inhibition in patients with relapsed or refractory B-cell malignancies. Although targeted agents have substantially improved both efficacy and safety outcomes, he notes that some patients still experience relapse, and the tolerability threshold in low-grade lymphomas, including chronic lymphocytic leukemia, has grown increasingly strict, with clinicians less willing to accept significant toxicity. Two needs follow: novel modes of action that remain effective after currently approved targeted drugs, and more selective, cleaner agents even within existing drug classes. He explains why two distinct strategies, targeted protein degradation and next-generation BCL2 inhibition paired with BTK inhibition, are generating interest, and characterizes the heavily pretreated, high-risk populations enrolled in both EHA 2026 readouts, including patients with TP53 aberrations or del(17p). Such patients face limited fixed-duration options in the relapse setting, defining the unmet need these regimens aim to address with deep, durable responses.